



**Press release**  
October 21, 2016  
Gothenburg

## Conference call on Interim Report

**Invitation to attend XVIVO Perfusion's conference call regarding the presentation of the Interim Report January – September 2016. The presentation will be held in English.**

Time: Thursday, October 27, 2016 at 3.00 p.m. CET

Registration can preferably be done in advance under the following link:  
<https://engage.vevent.com/rt/xvivoperfusion/index.jsp?seid=71>

or shortly before time of the conference starts on:  
Sweden dial in number: +46 (0)8-506 921 80  
International dial in number: +44 (0) 2071 928 000  
Conference name: XVIVO Perfusion, conference ID: 94108581

Participants from XVIVO Perfusion:  
Magnus Nilsson, CEO  
Christoffer Rosenblad, CFO

The press release for XVIVO Perfusion's Interim Report January – September 2016 will be released before the conference call October 27, 2016.

Before the conference call, slides will be available at the company web page, [www.xvivoperfusion.com/corporate/](http://www.xvivoperfusion.com/corporate/).

October 21, 2016  
Gothenburg  
XVIVO Perfusion AB (publ)

For further information, please contact  
Christoffer Rosenblad, CFO, +1 720 616 2101, [christoffer.rosenblad@xvivoperfusion.com](mailto:christoffer.rosenblad@xvivoperfusion.com)  
Magnus Nilsson, CEO, +46 31-788 21 50, [magnus.nilsson@xvivoperfusion.com](mailto:magnus.nilsson@xvivoperfusion.com)

---

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The Xvivo share is listed on NASDAQ First North Premier and has the ticker symbol XVIVO. More information can be found on the website [www.xvivoperfusion.com](http://www.xvivoperfusion.com). The Certified Adviser is Redeye, [www.redeye.se](http://www.redeye.se).

---

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.  
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.  
E-mail: [info@xvivoperfusion.com](mailto:info@xvivoperfusion.com). Website: [www.xvivoperfusion.com](http://www.xvivoperfusion.com)

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.